© Copyright Acquisition International 2025 - All Rights Reserved.

Article Image - Avant Diagnostics and Amarantus Diagnostics to Combine with Theranostics Health
Posted 7th March 2016

Avant Diagnostics and Amarantus Diagnostics to Combine with Theranostics Health

Avant Diagnostics, Inc, a biotechnology company focused on the development of oncology based diagnostics, and Amarantus Diagnostics, Inc, a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc, today announced that the companies have jointly entered into a letter of intent for Avant to acqu

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Avant Diagnostics and Amarantus Diagnostics to Combine with Theranostics Health
Image

Avant Diagnostics, Inc., a biotechnology company focused on the development of oncology based diagnostics, and Amarantus Diagnostics, Inc, a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc, today announced that the companies have jointly entered into a letter of intent for Avant to acquire assets and certain liabilities of Theranostics Health Incorporated, adding key CLIA laboratory and intellectual property capabilities to Avant’s previously announced letter of intent to merge with Amarantus Diagnostics (collectively, the “Transactions”).

THI currently generates over $1.5M in services revenue from some of the world’s leading biopharmaceutical companies, including 7 of the top 10 pharmaceutical companies by revenue. The companies will be holding a conference call to discuss the business combination today at 4:30 PM ET. To access the conference call please dial 215-383-1625 or toll free 800-356-8278; access code 135394.

Under the terms of the letter of intent, Avant shall issue to THI 25 million shares of its common stock upon the closing. Amarantus BioScience has provided a convertible note of $400,000 to THI to facilitate the transaction that will be assumed by Avant upon closing of the transactions. As previously disclosed, Avant plans to issue 80 million shares of its common stock to Amarantus Biosciences upon completion of its merger with Amarantus Diagnostics. The Transactions are expected to close in the first half of 2016, and are subject to customary closing conditions.

Gerald E. Commissiong, President & CEO of Amarantus said:

“THI is a leader in the area of signal transduction biology, where they have been able to attract an A-list of pharmaceutical customers collaborating with the company to evaluate the therapeutic benefit and potential of their drug candidates using THI’s proprietary assays.

“In addition, THI has a CLIA lab where Amarantus’ Diagnostics has established operations over the course of the first quarter that will allow for CLIA validation and commercial launch of the combined company’s suite of high-value, proprietary diagnostics in the areas of oncology and neurology. THI’s sales channel into the pharmaceutical industry will provide important leverage for the combined company to market the LymPro Test® for Alzheimer’s disease. We could not have picked a better partner to bring Avant and Amarantus’ Diagnostics leading-edge intellectual property in diagnostics and biomarkers to the market.”

Gregg Linn, President & CEO of Avant Diagnostics added:

“Key to the business case for the merged company is THI’s impressive pharma services revenue base and sales channel in the area of cell signaling biology. In addition to this, THI’s CLIA laboratory provides the combined company with the infrastructure to launch OvaDx®, MSPrecise® and LymPro Test in a regulatory compliant environment that has been vetted by some of the world’s top pharmaceutical companies. THI’s laboratory meets the highest quality standards under CLIA/CAP which should give both our pharmaceutical and commercial customers great confidence in the information generated in THI’s laboratory.”

THI’s core business is centred on providing pharmaceutical and biotechnical companies access to its technology for quantitatively measuring the activation status of key proteins and signal transduction pathways that are dysregulated in multiple disease processes via its Reverse-phase Protein Array (RPPA) platform. THI is experienced in running CAP-accredited assays in its CLIA laboratory for predicting response to therapies in difficult to treat cancers.  THI believes that, while genomic approaches may identify potential activating mutations in diseased tissues, measuring the actual activation status of the protein drug targets and the signal transduction pathways that they regulate, provides physicians with much-needed evidence that a particular therapeutic strategy can provide benefits to the patient.  THI has launched tests, TheraLink® Assays, for guiding therapeutic decisions in breast and colorectal cancer. The post-merger Avant Diagnostics will further build on its recognized scientific expertise in the area of cell cycle biology to increase its pharma services revenues and provide therapy guiding diagnostics in difficult to treat conditions.

Glenn Hoke, PhD, Chief Executive Officer of THI added:

“After an extensive evaluation of the diagnostics market, we believe that we have found the best potential partners in Avant and Amarantus. It is clear that we will be expanding our CLIA offerings with much needed tests such as OvaDx in cancer and MSPrecise in neurology, while also providing significant additional pharma services business development opportunities with the LymPro Test. With platforms in microarray proteomics, ELISA, flow cytometry and ‘next-gen’ sequencing, the combined company’s capabilities will allow it to add cross-platform diagnostics as we grow into the future.”

 

 

Categories: Innovation, M&A, Strategy


You Might Also Like
Read Full PostRead - Eye Icon
2016 Fund Awards FAQ
Finance
24/11/20152016 Fund Awards FAQ

2016 Fund Awards FAQ

Read Full PostRead - Eye Icon
Pamplona Capital Management Completes Acquisition of Loparex
Finance
14/08/2019Pamplona Capital Management Completes Acquisition of Loparex

Pamplona Capital Management (“Pamplona”) has completed its acquisition of Loparex from funds managed by Intermediate Capital Group (“ICG”), alongside members of the company’s leadership team, who remain committed to supporting the long-term growth of

Read Full PostRead - Eye Icon
The Perfect Storm for Pensioners
Finance
13/08/2015The Perfect Storm for Pensioners

Many retirees, and those on the cusp of retirement, should consider revising their personal financial strategy, warns the chief executive of one of the world’s largest independent financial advisory firms.

Read Full PostRead - Eye Icon
The History and Basics of Cost Segregation (Cost Seg)
Finance
22/02/2023The History and Basics of Cost Segregation (Cost Seg)

Cost segregation has a long and varied history, with its roots stretching back to the late-1800s. The concept was initially used as a way to help business owners save money on their taxes by splitting assets into different categories and leveraging the varying

Read Full PostRead - Eye Icon
Driving Force
News
16/04/2021Driving Force

Helping organizations to reduce collisions, injuries, license violations and total cost of fleet ownership through a patented driver risk management program, eDrivingSM is a clear market leader in its field. As the global enterprise celebrates twenty-five year

Read Full PostRead - Eye Icon
HMRC splashes a quarter of a million training staff to be hackers
Strategy
20/05/2021HMRC splashes a quarter of a million training staff to be hackers

HM Revenue & Customs has spent £262,251 on cyber security training for its staff over the two most recent financial years, according to official figures. This data was obtained and analysed under the Freedom of Information (FOI) act by the Parliament Stre

Read Full PostRead - Eye Icon
Quindell Plc Shares Suspended
Finance
29/06/2015Quindell Plc Shares Suspended

Shares in Insurance firm suspended after U.K Financial Conduct Authority confirms investigation.

Read Full PostRead - Eye Icon
Outsourcing:  A Tax Effective Solution
Finance
07/05/2015Outsourcing: A Tax Effective Solution

In recent years the tax affairs of large multinational organisations have been subject to greater scrutiny than ever before.

Read Full PostRead - Eye Icon
Falcon Certified Public Accountants
Finance
26/01/2017Falcon Certified Public Accountants

Falcon Certified Public Accountants Ltd., registered with the Hong Kong Institute of Certified Public Accountants, specialises in providing audit, tax and corporate advisory services to a wide range of clients. Founder Gilbert Loke talks us through the firm an



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have 14 unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow